Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
NCT ID: NCT02306837
Last Updated: 2016-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
40 participants
INTERVENTIONAL
2014-09-30
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01055301
Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation
NCT06324266
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
NCT01849783
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
NCT02086942
Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients
NCT02981199
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Consolidation chemo
Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
Bu-CY-E
mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bu-CY-E
mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG: 0-2
* Tbil \< 1.5x ULN and AST/ALT \<2.5x ULN
* With informed consent
Exclusion Criteria
* Women in pregnancy
* uncontrollable infection disease
* serum Cr \>400mmol/l
* uncontroled diabetis and heart disease
16 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiong HU
Head, Blood & Marrow Transplantation Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiong Hu, M.D,
Role: PRINCIPAL_INVESTIGATOR
Rui Jin Hospital, Shanghai Jiaotong Unic\versity School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rui Jin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, , China
Shanghai No 10 Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
JunMei Shi, M.D, Ph.D,
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Lym-Auto-RJH-2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.